63 Results for "

CR1

" in MedChemExpress (MCE) Product Catalog:
Products (63)

63 Results for "CR1" in MCE Product Catalog:

loading...
    loading...
24
24 Publications Verification
Cat. No.: HY-13848
CAS No.: 911715-90-7
Purity:  99.54%
Synonyms: AZD8797; KAND567
Target:  

CX3CR1 CXCR

AZD8797 (KAND567) is an allosteric non-competitive and orally active antagonist of the human CX3CR1 receptor; antagonizes CX3CR1 and CXCR2 with Kis of 3.9 and 2800 nM, respectively [1].
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-123918
CAS No.: 1380392-05-1
Purity:  99.59%
Target:  

CX3CR1

Research Areas:  

Endocrinology Cancer

JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. JMS-17-2 impairs metastatic seeding and colonization of breast cancer cells [1].
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-136453
CAS No.: 1352914-52-3
Purity:  98.38%
Research Areas:  

Cancer

CR-1-31-B is a synthetic rocaglate and a potent eIF4A inhibitor. CR-1-31-B exhibits powerful inhibitory effects over eIF4A by perturbing the interaction between eIF4A and RNA, sequentially impeding initiation during protein synthesis. CR-1-31-B perturbs association of Plasmodium falciparum eIF4A (PfeIF4A) with RNA. CR-1-31-B induces apoptosis of neuroblastoma and gallbladder cancer cells [1] .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15724
CAS No.: 698394-73-9
Purity:  98.26%
Synonyms: GSK-1605786; CCX282-B; Traficet-EN
Vercirnon (GSK1605786A) is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon inhibits CCR9-mediated Ca 2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 μM for all). Vercirnon is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively [1].
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15724A
CAS No.: 886214-18-2
Purity:  99.13%
Synonyms: GSK-1605786 sodium; CCX282-B sodium; Traficet-EN sodium
Target:  

CCR

Vercirnon (GSK1605786A) sodium is an orally bioavailable, selective, and potent antagonist of CCR9. Vercirnon sodium inhibits CCR9-mediated Ca 2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. Vercirnon sodium is selective for CCR9 over CCR1-12 and CX3CR1-7 (IC50s>10 μM for all). Vercirnon sodium is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively [1].
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-107456
CAS No.: 1427058-33-0
Purity:  ≥98.0%
Target:  

CX3CR1

E6130 is an orally active and highly selective CX3CR1 modulator, that may be effective for treatment of inflammatory bowel disease.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9928
CAS No.: 1245916-14-6
Synonyms: REGN 727; SAR 236553
Alirocumab is an anti-PCSK9 human monoclonal antibody. Alirocumab inhibits PCSK9. Alirocumab reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab improves atherosclerosis and inflammation [1] .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-W074890
CAS No.: 2441-41-0
Synonyms: N-palmitoyl glycine
Palmitoylglycine (N-palmitoyl glycine), an endogenous lipid that acts as a modulator of calcium influx and nitric oxide () production in sensory neurons. Palmitoylglycine is linked to an increased risk of Background Brugada syndrome (BrS) and interacts with BrS-associated proteins, demonstrating moderate binding affinities for DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA [1] .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P9928A
CAS No.: 1245916-14-6
Synonyms: REGN 727(anti-PCSK9); SAR 236553(anti-PCSK9)
Alirocumab (anti-PCSK9) is an anti-PCSK9 human monoclonal antibody. Alirocumab (anti-PCSK9) inhibits PCSK9. Alirocumab (anti-PCSK9) reduces NLRP3 inflammasome, regulates Nrf2/HO-1, HMGB1/NF-κB and Fractalkine/CX3CR1. Alirocumab (anti-PCSK9) increases the ability of the liver to bind LDL-cholesterol (LDL-C) and reduces levels of LDL-C in blood. Alirocumab (anti-PCSK9) improves atherosclerosis and inflammation [1] .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P82260
Synonyms: ADX; FDX; LOH11CR1D; FDX1; Ferredoxin 1 antibody; Adrenal ferredoxin antibody

Host:  

Rabbit

Application:  

WB, IHC-P, ICC/IF

Reactivity:  

Human, Mouse, Rat

loading...
    loading...
Cat. No.: HY-160421
CAS No.: 2000236-36-0
Target:  

Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

TREM2-IN-1 (OPA) is a TREM2 inhibitor derived from oxaliplatin and artesunate. TREM2-IN-1 can relieves immunosuppressive tumor microenvironment and enhancing chemical anticancer efficiency. TREM2-IN-1 deters the tumor growth in mice models bearing MC38 colorectal tumor by reducing the number of CD206 + and CX3CR1 + immunosuppressive macrophages. TREM2-IN-1 also promotes the expansion and infiltration of immunostimulatory dendritic, cytotoxic T and natural killer cells [1].
loading...
    loading...
Cat. No.: HY-175746
CAS No.: 3036141-78-0
Target:  

CX3CR1

Research Areas:  

Cardiovascular Disease

AZD0233 is an orally active CX3CR1 antagonist. AZD0233 modulates the CX3CR1/CX3CL1 signaling axis via immunomodulatory effects. AZD0233 has improved physicochemical properties, metabolic stability, low toxicity and CYP inhibition. AZD0233 improves cardiac function and reduces macrophages and fibrotic scar in mice model of dilated cardiomyopathy. AZD0233 can be used for cardiovascular diseases like dilated cardiomyopathy research [1].
loading...
    loading...
Cat. No.: HY-P99404
CAS No.: 2084037-83-0
Synonyms: E6011

Target:  

CXCR

Research Areas:  

Inflammation/Immunology Cancer

Quetmolimab (E6011) is a humanized anti-Fractalkine (CX3CL1) monoclonal antibody. Quetmolimab binds to membrane-bound and soluble Fractalkine, neutralizes Fractalkine-induced migration of CX3CR1-expressing cells, mediates target-bound complex elimination from serum. Quetmolimab suppresses free soluble Fractalkine levels in cynomolgus monkeys, with target engagement linked to increased serum total Fractalkine concentration. Quetmolimab can be used for the research of Crohn’s disease, rheumatoid arthritis, and primary biliary cholangitis [1].
loading...
    loading...
Cat. No.: HY-RS03131
Research Areas:  

Others

CR1 Human Pre-designed siRNA Set A contains three designed siRNAs for CR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-W074890R
CAS No.: 2441-41-0
Synonyms: N-palmitoyl glycine (Standard)
Palmitoylglycine (Standard) is the analytical standard of Palmitoylglycine. This product is intended for research and analytical applications. Palmitoylglycine (N-palmitoyl glycine), an endogenous lipid that acts as a modulator of calcium influx and nitric oxide () production in sensory neurons. Palmitoylglycine is linked to an increased risk of Background Brugada syndrome (BrS) and interacts with BrS-associated proteins, demonstrating moderate binding affinities for DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA[1][2][3].
loading...
    loading...
Cat. No.: HY-RS03380
Research Areas:  

Others

Cx3cr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Cx3cr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-P2969
CAS No.: 80295-66-5
Target:  

Endogenous Metabolite

Research Areas:  

Metabolic Disease

Complement factor I is a serine protease that downregulates complement activity in the fluid phase and/or on cell surfaces in conjunction with one of its cofactors, factor H (FH), complement receptor 1 (CR1/CD35), C4 binding protein (C4BP) or membrane cofactor protein (MCP/CD46) [1].
loading...
    loading...
Cat. No.: HY-168975
CAS No.: 2408145-38-8
Target:  

CX3CR1

Research Areas:  

Inflammation/Immunology

Fosrugocrixan is an antagonist for CX3C chemokine receptor 1 (CX3CR1) that exhibits anti-inflammatory activity [1].
loading...
    loading...
Cat. No.: HY-136453A
CAS No.: 1352914-53-4
Purity:  99.92%
Target:  

Mucin Drug Isomer

Research Areas:  

Cancer

CR-1-30-B is an inactive enantiomer of CR-1-31-B. CR-1-30-B, as a control, is inactive against eIF4A and has no apparent effect on the induction of MUC1-C translation [1].
loading...
    loading...